FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1587698873> ?p ?o ?g. }

• W1587698873 abstract "Nowadays, lung cancer is the malignant tumor of the highest morbidity and mortality over the world, and non-small cell lung cancer (NSCLC) makes up about 80%. There is a great many NSCLC patients have been in advanced stage when diagnosed. As a result, people pay more attention to curing advanced NSCLC. The standard treatment to advanced NSCLC is platinum-based combined chemotherapy. However, chemotherapy drugs usually have limited effects on improving the survival of the patients. Then exploring new therapies is extremely urgent to us. Now, molecular targeted therapy has been the most promising research area for the treatment of NSCLC with researches going deep into pathogenesis and biological behavior of lung cancer. Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have achieved a great success in the treatment of advanced NSCLC. Their representatives are erlotinib and gefitinib. The two drugs have been widely used to treat advanced NSCLCs worldwide, especially for the patients with EGFR activating mutations. However, after a period of treatment (median time is 6 to 12 months), most patients will develop drug resistance to EGFR-TKIs. Intense research in these NSCLCs has identified two major mechanisms of resistance to TKIs: primary and acquired resistances. The research about resistance mechanism of NSCLC to EGFR-TKIs is a hot one because of their excellent effects on improving overall and progression-free survival. The aim of this article was to summarize the development of the resistance mechanisms. 目前，肺癌是全世界范围内发病率和死亡率最高的恶性肿瘤，其中非小细胞肺癌（non-small cell lung cancer, NSCLC）占全部肺癌的80%左右，而NSCLC患者中有很大一部分在确诊时已经处于晚期。因此，对于晚期NSCLC的治疗也越来越受到人们的重视。虽然晚期NSCLC的标准治疗为含铂双药联合化疗，但是化疗药物对改善晚期NSCLC患者的生存期方面作用十分有限，因此寻求新的治疗方式迫在眉睫。随着对肺癌发病机制及其生物学行为的深入研究，分子靶向治疗已成为治疗晚期NSCLC最具前景的研究领域。其中表皮生长因子受体-酪氨酸激酶抑制剂（epidermal growth factor receptor tyrosine kinase inhibitors, EGFR-TKIs）在晚期NSCLC治疗方面取得了突破性进展，其代表药物为吉非替尼和厄洛替尼，这两种EGFR-TKIs已在全世界范围内得到认可并被广泛用于晚期NSCLC的治疗，尤其是对于EGFR敏感突变者。然而，经过一段时间（中位时间为6个月-12个月）的治疗后，大部分患者会对EGFR-TKIs产生耐药，其耐药机制主要包括原发性和获得性耐药。由于EGFR-TKIs在改善晚期NSCLC患者总生存期和无进展生存期方面的突出作用，对于EGFR-TKIs耐药机制的探索已成为国内外研究的热点。该文章就EGFR-TKI耐药机制的研究进展进行了综述。" @default.
• W1587698873 created "2016-06-24" @default.
• W1587698873 creator A5008736377 @default.
• W1587698873 creator A5043365458 @default.
• W1587698873 creator A5046784859 @default.
• W1587698873 creator A5047055826 @default.
• W1587698873 creator A5047606095 @default.
• W1587698873 creator A5050541922 @default.
• W1587698873 creator A5064887006 @default.
• W1587698873 creator A5065380119 @default.
• W1587698873 creator A5090482004 @default.
• W1587698873 date "2013-10-20" @default.
• W1587698873 modified "2023-09-25" @default.
• W1587698873 title "[Research progress of the resistance mechanism of non-small cell lung cancer to EGFR-TKIs]." @default.
• W1587698873 cites W1967394241 @default.
• W1587698873 cites W1977332018 @default.
• W1587698873 cites W1980497534 @default.
• W1587698873 cites W1981691521 @default.
• W1587698873 cites W1985264867 @default.
• W1587698873 cites W1990938833 @default.
• W1587698873 cites W1998971866 @default.
• W1587698873 cites W1999909760 @default.
• W1587698873 cites W2004295816 @default.
• W1587698873 cites W2007661090 @default.
• W1587698873 cites W2012944100 @default.
• W1587698873 cites W2018628280 @default.
• W1587698873 cites W2034380694 @default.
• W1587698873 cites W2059890247 @default.
• W1587698873 cites W2063874384 @default.
• W1587698873 cites W2064966341 @default.
• W1587698873 cites W2068244265 @default.
• W1587698873 cites W2082592896 @default.
• W1587698873 cites W2086468784 @default.
• W1587698873 cites W2087955215 @default.
• W1587698873 cites W2096164218 @default.
• W1587698873 cites W2096786080 @default.
• W1587698873 cites W2103098489 @default.
• W1587698873 cites W2103514020 @default.
• W1587698873 cites W2105026490 @default.
• W1587698873 cites W2106391833 @default.
• W1587698873 cites W2111580893 @default.
• W1587698873 cites W2111599976 @default.
• W1587698873 cites W2119351872 @default.
• W1587698873 cites W2121389354 @default.
• W1587698873 cites W2123611729 @default.
• W1587698873 cites W2126004255 @default.
• W1587698873 cites W2127766722 @default.
• W1587698873 cites W2133867160 @default.
• W1587698873 cites W2139110945 @default.
• W1587698873 cites W2140334822 @default.
• W1587698873 cites W2141088968 @default.
• W1587698873 cites W2142850084 @default.
• W1587698873 cites W2147699387 @default.
• W1587698873 cites W2150735425 @default.
• W1587698873 cites W2153345506 @default.
• W1587698873 cites W2160300997 @default.
• W1587698873 cites W2171313739 @default.
• W1587698873 doi "https://doi.org/10.3779/j.issn.1009-3419.2013.10.07" @default.
• W1587698873 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6015174" @default.
• W1587698873 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24113007" @default.
• W1587698873 hasPublicationYear "2013" @default.
• W1587698873 type Work @default.
• W1587698873 sameAs 1587698873 @default.
• W1587698873 citedByCount "5" @default.
• W1587698873 countsByYear W15876988732014 @default.
• W1587698873 countsByYear W15876988732017 @default.
• W1587698873 countsByYear W15876988732018 @default.
• W1587698873 countsByYear W15876988732020 @default.
• W1587698873 countsByYear W15876988732021 @default.
• W1587698873 crossrefType "journal-article" @default.
• W1587698873 hasAuthorship W1587698873A5008736377 @default.
• W1587698873 hasAuthorship W1587698873A5043365458 @default.
• W1587698873 hasAuthorship W1587698873A5046784859 @default.
• W1587698873 hasAuthorship W1587698873A5047055826 @default.
• W1587698873 hasAuthorship W1587698873A5047606095 @default.
• W1587698873 hasAuthorship W1587698873A5050541922 @default.
• W1587698873 hasAuthorship W1587698873A5064887006 @default.
• W1587698873 hasAuthorship W1587698873A5065380119 @default.
• W1587698873 hasAuthorship W1587698873A5090482004 @default.
• W1587698873 hasConcept C114851261 @default.
• W1587698873 hasConcept C121608353 @default.
• W1587698873 hasConcept C126322002 @default.
• W1587698873 hasConcept C143998085 @default.
• W1587698873 hasConcept C2776256026 @default.
• W1587698873 hasConcept C2776694085 @default.
• W1587698873 hasConcept C2778087573 @default.
• W1587698873 hasConcept C2779438470 @default.
• W1587698873 hasConcept C2780580887 @default.
• W1587698873 hasConcept C2781230642 @default.
• W1587698873 hasConcept C71924100 @default.
• W1587698873 hasConcept C86803240 @default.
• W1587698873 hasConcept C89423630 @default.
• W1587698873 hasConceptScore W1587698873C114851261 @default.
• W1587698873 hasConceptScore W1587698873C121608353 @default.
• W1587698873 hasConceptScore W1587698873C126322002 @default.
• W1587698873 hasConceptScore W1587698873C143998085 @default.
• W1587698873 hasConceptScore W1587698873C2776256026 @default.
• W1587698873 hasConceptScore W1587698873C2776694085 @default.
• W1587698873 hasConceptScore W1587698873C2778087573 @default.
• W1587698873 hasConceptScore W1587698873C2779438470 @default.

• next